Literature DB >> 3275814

A reappraisal of nitrate therapy.

J Abrams1.   

Abstract

Nitroglycerin and the long-acting nitrates are beneficial in stable and unstable angina pectoris and acute myocardial infarction and as adjunctive therapy in congestive heart failure. Nitroglycerin compounds relax vascular smooth muscle, producing venous, arterial, and arteriolar dilatation. These actions are modulated by stimulation of intracellular cyclic guanosine monophosphate. Nitrate efficacy in ischemic heart disease is due to peripheral venous and arterial vasodilatation that results in decreased myocardial oxygen consumption. Nitrates also dilate coronary arteries and collaterals, reverse coronary vasoconstriction, and enlarge some coronary atherosclerotic lesions. Nitrates improve exercise performance in stable angina pectoris. Intravenous nitroglycerin should be used in the initial treatment of unstable angina. Nitrates may be beneficial in myocardial infarction for control of ischemic pain, acute hypertension, and left ventricular failure. In subjects with congestive heart failure, nitrates reduce symptoms and improve exercise tolerance. Nitrate tolerance is a problem with continuous nitrate therapy. Tolerance is most likely to occur with frequent dosing or the use of long-acting nitrates, particularly transdermal nitroglycerin disks, and can be prevented or reversed with intermittent-dosing regimens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275814

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  9 in total

Review 1.  Transdermal nitroglycerin. Does it really work in the treatment of angina?

Authors:  A Fletcher
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

2.  [Not Available].

Authors:  D Gossard; J C Tardif
Journal:  Can Fam Physician       Date:  1991-03       Impact factor: 3.275

Review 3.  Endogenous and exogenous nitrates and their role in myocardial ischaemia.

Authors:  T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

4.  Inhibition of platelet-derived mitogen release by nitric oxide (EDRF).

Authors:  M L Barrett; A L Willis; J R Vane
Journal:  Agents Actions       Date:  1989-06

Review 5.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

6.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.

Authors:  T Münzel; S Kurz; S Rajagopalan; M Thoenes; W R Berrington; J A Thompson; B A Freeman; D G Harrison
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

Review 7.  Short and long-acting oral nitrates for stable angina pectoris.

Authors:  U Thadani; R J Lipicky
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

8.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.

Authors:  T Münzel; H Sayegh; B A Freeman; M M Tarpey; D G Harrison
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 9.  Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Authors:  Andreas Daiber; Thomas Münzel
Journal:  Antioxid Redox Signal       Date:  2015-09-24       Impact factor: 8.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.